Publications
2025
- Wang X, Klaassen CD, Chen X, Zhang Y:
"Pathological and therapeutic roles of bile acid metabolism and signaling in hepatocellular carcinoma: Insights from human and mouse studies."
Pharmacol Rev. 2025 Jun 6;77(5):100073. doi: 10.1016/j.pharmr.2025.100073. Epub ahead of print. PMID: 40602290. | Pubmed Link - Lehrich BM, Delgado ER, Yasaka TM, Liu S, Cao C, Liu Y, Taheri MN, Guan X, Koeppen H, Singh S, Meadows V, Liu JJ, Singh-Varma A, Krutsenko Y, Poddar M, Hitchens TK, Foley LM, Liang B, Rialdi A, Rai RP, Patel P, Riley M, Bell A, Raeman R, Dadali T, Luke JJ, Guccione E, Ebrahimkhani MR, Lujambio A, Chen X, Maier M, Wang Y, Broom W, Tao J, Monga SP:
"Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers."
Nat Commun. 2025 May 30;16(1):5009. doi: 10.1038/s41467-025-60457-2. | Pubmed Link - Turnham RE, Pitea A, Jang GM, Xu Z, Lim HC, Choi AL, Von Dollen J, Levin RS, Webber JT, McCarthy E, Hu J, Li X, Che L, Singh A, Yoon A, Chan G, Kelley RK, Swaney DL, Zhang W, Bandyopadhyay S, Theis FJ, Eckhardt M, Chen X, Shokat KM, Ideker T, Krogan NJ, Gordan JD:
“HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma”.
Cancer Research. 2025 Feb 17;85(4):660-674 | PubMed link - Liao W, Zhang Y, Wang J, Cui G, Evert M, Xu M, Wu Y, Wang X, Zhao J, Deng S, Song X, Monga SP, Zhao J, Li Q, Calvisi DF and Chen X:
“β-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans”
Hepatology, Epub Feb. 2025 | Pubmed link - Lu X, Zhang Y, Xue J, Evert M, Calvisi D, Chen X, Wang X:
“MAD2L1 supports MYC-driven liver carcinogenesis in mice and predicts poor prognosis in human hepatocarcinoma”
Toxicological Sciences, 2025 Jan 1; 203(1):41-51 | PubMed link - Xu M, Calvisi DF, Chen X:
“Splicing, Signaling, and Survival: The Role of RBM39 in Cholangiocarcinoma Progression”
Cell Mol Gastroenterol Hepatol. Vol. 19(1). Jan. 2025:101419 | Pubmed link
2024
- Zhou Y, Zhang S, Qiu G, Wang X, Yonemura A, Xu H, Gui G, Deng S, Chun J, Chen N, Xu M, Song X, Wang J, Xu Z, Deng Y, Evert M, Calvisi DF, Lin S, Wang H and Chen X:
“TSC/mTORC1 mediates mTORC2/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M”
Journal of Clinical Investigation, Epub Sept. 2024 | Pubmed link - Cigliano A, Gigante I, Serra M, Vidili G, Simile MM, Steinmann S, Urigo F, Cossu E, Pes GM, Dore MP, Ribback S, Milia EP, Pizzuto E, Mancarella S, Che L, Pascale RM, Giannelli G, Evert M, Chen X and Calvisi DF:
“HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma”
Journal of Experimental & Clinical Cancer Research, Vol. 43(1) , Sept. 2024:253 | Pubmed link - Zhao W, Wang X, Ha L, Zhang C, Wang C, Xu T, Bo Y, Zhang M, Kong D, Yee SW, Stahl A, Chen X and Zhang Y:
“SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis”
Nature Communication, Vol. 15(1) , Aug. 2024:7522 | Pubmed link - Cigliano A, Liao W, Deiana GA, Rizzo D, Chen X and Calvisi DF:
“Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges”
Biomedicines. Vol 12(7); Jul. 2024: 1624 | Pubmed link - Huang P, Wei G, Kirkpatrick JD, Lin Y, Tan L, Matta H, Nasser I, Huang M, Chen L, Petitjean M, Skelton-Badlani D, Gao W, Vaid K, Zhang S, Lugovaskoy A, Alenzi M, Chen X, Gores GJ and Popov YV:
“Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis”
Journal of Hepatology, Epub Jul. 2024 | Pubmed Link - Cigliano A, Simile MM, Vidili G, Pes GM, Dore MP, Urigo F, Steinmann SM, Che L, Feo C, Pascale RM, Ribback S, Evert M, Chen X and Calvisi DF:
“Fatty acid synthase promotes the growth of hepatocellular carcinoma cells by regulating the SKP2/27KIP1 axis”
Medicina, Vol. 60 (7); Jul. 2024:1160 | Pubmed Link - Deng S, Lu X, Wang X, Liang B, Xu H, Yang D, Gui G, Yonemura D, Paine H, Zhou Y, Zhang Y, Simile MM, Urigo F, Evert M, Calvisi DF, Green BL and Chen X:
“Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma”
Cell Death and Disease, Epub. Jun. 2024 | Pubmed link - Zhang R, Li S, Schippers K, Li Y, Eimers B, Lavrijsen M, Wang L, Cui G, Chen X, Peppelenbosch MP, Lebbink JHG, Smits R:
“Analysis of tumor-associated AXIN1 missense mutations identifies variants that activate β-Catenin signaling”
Cancer Research, Vol. 84(9); May, 2024, pp1443-1459 | PubMed Link - Tomlinson JL, Li B, Yang J, Loeuillard E, Kupers H, Watkins RD, Carlson DM, Wilhite J, O’Brien DR, Graham RP, Chen X, Smoot RL, Dong H, Gores GJ and Ilyas SI:
“Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Cholangiocarcinoma”
Journal of Hepatology, Epub Mar. 2024 | Pubmed Link - Shihadih D, Wang X, Zushin PJH, Khodakivskyi P, Park HM, Tso E, Shiblak J, Misic A, Louie SM, Ward C, Hellestern M, Normura DK, Goun E, Urigo F, Calvisi DF, Chen X and Stahl A:
"FATP5 is indispensable for the growth of intrahepatic cholangiocarcinoma"
Molecular Cancer Research, Epub Feb. 2024 | Pubmed Link - Setayesh T, Vaziri F, Hu Y, Chen X, Lia J, We D and Wan YJY:
“Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma”
Acta Pharmaceutica Sinica B, Vol. 14(1); Jan. 2024, pp292-303 | Pubmed link
2023
- Klemm S, Evert K, Utpatel K, Chen X, Evert M, Calvisi DF and Scheiter A:
“Identification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis”
BMC Cancer, Vol. 23(1); Nov. 2023:1086 | Pubmed link - Yi Zhou, Cui G, Xu H, Chun J, Zhang Z, Yang D, Zhang Z, Yang L, Wang J, Wan M, Calvisi DF, Lin S, Chen X# and Wang H# (#Co-corresponding authors):
“Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis”
Cell Death and Disease, Epub Jul. 2023 | Pubmed link - Liao W, Calvisi DF and Chen X:
“A new mission for an old anti-cancer drug: harnessing hepatocyte-specific metabolic pathways against liver tumors”
Signal Transduction and Targeted Therapy, Vol. 8(1). Jun. 2023:240 | Pubmed Link - Hu Y, Setayesh T, Vaziri F, Wu X, Hwang ST, Chen X and Wan YJY:
“miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism”
Molecular Therapy, Epub May 2023 | Pubmed Link - Lu X, Deng S, Xu J, Zhang H, Cui G, Zhou Y, Zhang Y, Xu H, Zhang F, Mao R, Zhong S, Cramer T, Evert M, Calvisi DF, He Y, Liu C and Chen X:
“Combination of AFP vaccine and immune checkpoint inhibitors for hepatocellular carcinoma treatment”
Journal of Clinical Investigation, Epub Apr. 2023 | Pubmed Link - Liao W, Calvisi DF and Chen X:
“Year in review: Liver cancer research in 2022: tumor microenvironment takes the central stage”
Hepatology Communications, Vol. 7(3). Feb. 2023: e0074 | Pubmed Link - Calvisi DF, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues PM, Coulouarn C, Castro RE, Segatto O, Raggi C, van der Laan LJW, Carpino G, Goeppert B, Roessler S, Kendall TJ, Evert M, Gonzales-Sanchez E, Valle JW, Vogel A, Bridgewater J, Borad MJ, Gores GJ, Robert LR, Marin JJG, Andersen JB, Alvaro D, Forner A, Banales JM, Cardinale V, Macias RIR, Vicent S, Chen X, Braconi C, Verstegen MMA and Fouassier L (CCA model consortium):
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Review Gastroenterology and Hepatology, Epub Feb. 2023 | Pubmed Link - Ament CE, Steinmann S, Evert K, Pes GM, Ribback S, Gigante I, Pizzuto E, Banales J, Rodrigues P, Olaidola P, Wang H, Giannelli G, Chen X, Evert M and Calvisi DF:
Aberrant fucosylation sustains the NOTCH and EGFR/NF-κB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma
Hepatology, Epub Feb. 2023 | Pubmed Link
2022
- Dai W, Shen J, Yan J, Bott AJ, Maimouni S, Daguplo HQ, Wang Y, Khayati K, Guo JY, Zhang L, Wang Y, Valvezan A, Ding WX, Chen X, Su X, Gao S and Zong WX
“Glutamine synthetase limits tumor growth of β-Catenin-mutated liver cancers by maintaining nitrogen homeostasis”
Journal of Clinical Investigation, Vol. 132(24); Dec. 2022: e161408 | Pubmed Link - Mancarella S, Gigante I, Serino G, Pizzuto, Dituri F, Valentini MF, Wang J, Chen X, Armentano R, Calvisi DF and Giannelli G
“Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA via TGF-β inhibition”
Journal of Experimental & Clinical Cancer Research, Vol. 41(1) , Nov. 2022: 331 | Pubmed Link - Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF and Chen X
β-Catenin signaling in hepatocellular carcinoma
Journal of Clinical Investigation, Vol. 132(4); Feb. 2022; e154515 | Pubmed Link - Sandi Kwee and Chen X
Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities
Hepatoma Research, Vol. 8:32; Aug. 2022 | Pubmed Link - Liang B, Wang H, Qiao Y, Qian M, Song X, Zhou Y, Zhang Y, Shang R, Che L, Chen Y, Huang Z, Wu H, Monga SP, Zeng Y, Calvisi DF, Chen X and Chen X
Differential requirement of Hippo cascade during CTNNB1 and AXIN1 mutation during hepatocarcinogenesis
Hepatology, Epub Aug. 2022 | Pubmed link - Seo Y, Craig M, Murphy ST, Feng J, Chen X and Yuneva M
[18F]-(2S,4R)4-fluoroglutamine PET Imaging of Glutamine Metabolism in Murine Models of Hepatocellular Carcinoma (HCC)
Molecular Imaging, Jul. 2022:518951 | Pubmed link - Cigliano A, Zhang S, Ribback S, Steinmann, S, Sini M, Ament CE, Utpatel K, Song X, Wang J, Pilo MP, Berger F, Wang H, Tao J, Li X, Pes GM, Mancarella S, Giannelli G, Dombrowski F, Evert M, Calvisi DF, Chen X and Evert K
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
Journal of Experimental & Clinical Cancer Research, Vol. 41(1) , Jun. 2022: 192 | Pubmed Link - Zhang Y, Xu H, Liang B, Chen X, Ko S, Gui G, Wang P, Wang H, Xu M, Wnag J, Pes GM, Ribback S, Zeng Y, Singhi A, Monga SP, Evert M, Tang L, Calvisi DF and Chen X
β-Catenin sustains and is required for YAP oncogenic activity in cholangiocarcinoma
Gastroenterology, Epub Apr. 2022 | Pubmed link - Wang H, Zhou Y, Xu H, Wang X, Zhang Y, Shang R, O’Farrell M, Roessler S, Sticht C, Stahl A, Evert M, Calvisi DF, Zeng Y and Chen X
Therapeutic efficacy of FANS inhibition in preclinical models of HCC
Hepatology, Epub Jan. 2022 | Pubmed link - Scheiter A, Evert K, Reibenspies L, Cigliano A, Annweiler K, Muller K, Pohmerer LMG, Xu H, Cui G, Itzel T, Materna-Reichelt S, Coluccio A, Honarnejad K, Teufel, Brochhausen C, Donbrowski, Chen X, Evert M, Calvisi DF and Utpatel K
RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues
Molecular Oncology, Vol. 16(5), Mar. 2022, pp1091-1118 | Pubmed link
2021
- Xu H, Chen K, Shang R, Chen X, Zhang Y, Song X, Evert M, Zhong S, Li B, Calvisi DF and Chen X
Alpelisib combination treatment as novel targeted therapy against hepatocellar carcinoma
Cell death and disease, Vol.12(10), Oct. 2021:920 | PubMed Link | Link to the Journal - Wang H, Zhang S, Zhang Y, Jia J, Wang J, Liu X, Zhang J, Song X, Che L, Ribback S, Cigliano A, Evert M, Liang B, Wu H, Calvisi DF, Zeng Y and Chen X
TAZ is indispensable for hepatocarcinogenesis induced by c-MYC
Journal of Hepatology, Epub Aug. 2021 | PubMed Link | Link to the Journal - Wang H, Chen X and Calvisi DF
Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics
Expert Opinion on Therapeutic Targets, Vol. 25(8); Aug. 2021; pp645-658 | PubMed Link | Link to the Journal - Zhou Y, Tao J, Calvisi DF and Chen X
Role of lipogenesis rewiring in hepatocellular carcinoma
Seminars in Liver Disease, Epub Jul. 2021 | PubMed Link | Link to the Journal - Song X, Wang P, Wang J, Affo S, Wang H, Xu M, Schwabe RF, Chang TT, Bogl M, Pes GM, Ribback S, Evert M, Chen X# and Calvisi DF# (#Co-corresponding authors):
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation
Journal of Hepatology, Epub May, 2021 | PubMed Link | Link to the Journal - Lu X, Peng B, Chen Ge, Pes MG, Ribback S, Pal R, Evert M, Calvisi DF, Chen X, Fan B and Wang J
YAP accelerates NOTCH driven cholangiocarcinogenesis via mTORC1 in mice
American Journal of Pathology, Epub Jun. 2021 | PubMed Link | Link to the Journal - Pocaterra A, Scattolin G, Romani R, Ament C, Ribback S, Chen X, Evert M, Calvisi DF and Supont S
Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development
Communications Biology, Epub Jun. 2021 | PubMed Link | Link to the Journal - Cigliano A, Chen X and Calvisi DF
Current challenges to underpinning the genetic basis for cholangiocarcinoma
Expert Review of Gastroenterology and Hepatology, Vol. 15(5); May. 2021: pp511-526 | PubMed Link | Link to the Journal - Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, Caviglia JM, Yu L, Yin D, Savage T, Wells RG, Mack M, Zender L, Arpair N, Remotti HE, Rabadan R, Leblond AL, Weber A, Llover JM, Sia D, Seki E, Chen X, Califano A, and Schwabe RF
Promoting of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations
Cancer Cell, Epub Apr. 2021 | PubMed Link | Link to the Journal - Wang H, Calvisi DF and Chen X
Organoids for the study of liver cancer
Seminars in Liver Disease Vol. 41(1); Jan. 2021; pp19-27 | PubMed Link | Link to the Journal - Zhang Y, Solinas A, Cairo S, Evert M, Chen X, and Calvisi DF
Molecular mechanisms of hepatoblastoma
Seminars in Liver Disease, Vol. 41(1); Jan. 2021; pp28-41 | PubMed Link | Link to the Journal - Tao J, Krutsenko Y, Moghe A, Singh S, Poddar M, Bell A, Oertel M, Singhi AD, Geller D, Chen X, Lujkamibio A, Liu S and Monga SP
Nrf2 and β-catenin coactivation in hepatocellular cancer: Biological and therapeutic implications
Hepatology, Epub Feb. 2021 | PubMed Link | Link to the Journal - Zhang Y, Liang B, Song X, Wang H, Evert M, Zhou Y, Calvisi DF, Tang L and Chen X
Loss of Apc cooperates with activated oncogenes to induce liver tumor formation in mice
American Journal of Pathology, Epub Feb. 2021 | PubMed Link | Link to the Journal - Wang H, Wang P, Xu M, Song X, Wu H, Evert M, Calvisi DF, Zeng Y and Chen X
Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression
Cell death and disease, Epub Feb. 2021 | PubMed Link | Link to the Journal - Liang B, Zhou Y, Qian M, Xu M, Wang J, Zhang Y, Song X, Wang H, Lin S, Ren C, Monga SP, Wang B, Evert M, Chen Y, Chen X, Huang Z, Calvisi DF and Chen X
TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis
Journal of Hepatology, Epub Feb. 2021 | PubMed Link | Link to the Journal
2020
- Chen X, Kiss A, Schaff Z, Evert K, Zhang Y, Zhong S, Evert M, Calvisi DF and Chen X
CDK9 is dispensable for Yap-driven Hepatoblastoma development
Pediatric Blood and Cancer, May; 67(5). 2020: e28221 | PubMed Link | Link to the Journal - Wang H, Song X, Liao H, Wang P, Zhang Y, Che L, Zhang J, Zhou Y, Cigliano An, Amert C, Superville D, Ribback S, Reeves M, Pes GM, Liang B, Wu H, Evert M, Calvisi DF and Chen X
Overexpression of SMAD7 activates the YAP/NOTCH cascade and promotes liver carcinogenesis in mice and humans
Hepatology, Epub Dec. 2020 | PubMed Link | Link to the Journal - Jia J, Che L, Cigliano A, Wang X, Peitta G, Tao J, Zhong S, Ribback S, Evert M, Calvisi DF and Chen X
Pivotal role of fatty acid synthase alone c-Myc driven hepatocarcinogenesis
International Journal of Molecular Sciences, Vol. 21(22), Nov. 2020: 8467 | PubMed Link | Link to the Journal - Wang H, Wang J, Zhang S, Jia J, Liu X, Zhang J, Wang P, Song X, Che L, Liu K, Ribback S, Cigliano A, Evert M, Calvisi DF, Zeng Y and Chen X
Distinct and overlapping roles of Hippo effectors YAP and TAZ during human and mouse hepatocarcinogenesis
Cellular and Molecular Gastroenterology and Hepatology, Epub Nov. 2020 | PubMed Link | Link to the Journal - Shang R, Song X, Wang P, Zhou Y, Lu X, Xu M, Chen X, Utpatel K, Lu X, Che L, Liang B, Cigliano A, Evert M, Wang D, Calvisi DF and Chen X
Cabozantinib based combination therapy for the treatment of hepatocellular carcinoma
Gut, Epub Nov. 2020 | PubMed Link | Link to the Journal - Méndez-Lucas A, Lin W, Driscoll PC, Legrave N, Vilaseca LN, Xie C, Charles M, Wilsdon Z, Jones NP, Rayport S, Rodríguez-Justo M, Li V, MacRae N, Chen X and Yuneva M
Identifying strategies to target the metabolic flexibility of tumors
Nature Metabolism, Vol. 2(4), Apr. 2020, pp335-350 | PubMed Link | Link to the Journal - Kido T, Tabatabai L, Chen X and Lau YFC
Potential dual functional roles of the Y-linked RBMY in hepatocarcinogenesis
Cancer Science, Epub May, 2020 | PubMed Link | Link to the Journal - Lu X, Paliogiannis P, Calvisi DF and Chen X.
Role of the mTOR pathway in liver cancer: from molecular genetics to targeted therapies
Hepatology, Epub May, 2020 | PubMed Link | Link to the Journal - Zhang S, Zhang J, Evert K, Li X, Liu P, Kiss A, Schaff Z, Ament C, Zhang Y, Serra M, Evert M, Chen N, Xu F, Chen X, Tao J, Calvisi DF and Cigliano A
The hippo effector TAZ cooperates with oncogenic β-catenin to induce hepatoblastoma development in mice and humans
American Journal of Pathology, Epub Apr. 2020 | PubMed Link | Link to the Journal - Zhou Y, Xu M, Liu P, Wang H, Song X, Che L, Calvisi DF, Lin S and Chen X
mTORC2 signaling is required for liver regeneration in a cholestatic liver injury murine model
American Journal of Pathology, Epub Apr. 2020 | PubMed Link | Link to the Journal - Xu M, Wang H, Sang R, Wang P, Zhou Y, Li R, Liang, L, Evert K, Uptatel K, Xu Z, Wang J, Song X, Che L, Calvisi DF, Chen X, Zhen Y and Chen X
mTORC2 signaling is necessary for timely liver regeneration after partial hepatectomy
American Journal of Pathology, Epub Feb. 2020 | PubMed Link | Link to the Journal - Mancarella S, Serino G, Dituri F, Cigliano A, Ribback S, Wang J, Chen X, Diego Calvisi and Giannelli G
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
Cell Death and Differentiation, Epub Feb. 2020 | PubMed Link | Link to the Journal
- Wang P, Song X, Cao D, Cui K, Wang J, Utpatel K, Shang R, Wang H, Che L, Evert M, Zhao K, Calvisi DF and Chen X
Oncogene-dependent function of BRG1 in hepatocarcinogenesis
Cell Death and Disease, Feb. 2020, 11(2):91 | PubMed Link | Link to the Journal - Chen B, Garmire L, Calvisi DF, Chua MS, Kelley R and Chen X
Harnessing big omics data and AI for drug discovery in hepatocellular carcinoma
Nature Review Gastroenterology and Hepatology, Epub Jan. 2020. | PubMed Link | Link to the Journal
2019
- Che L, Paliogiannis P, Cialiano A, Pilo MG, Chen X, and Calvisi DF
Pathogenetic, prognostic and therapeutic role of Fatty Acid Synthase in human hepatocellular carcinoma
Frontiers in Oncology, Dec. 2019; 9:1412| PubMed Link | Link to the Journal - Liu P, Liang B, Liu M, Lebbink JHG, Li S, Qian M, Lavrigsen M, Peppelenbosch M, Chen X, and Smits R
Oncogenic mutations in armadillo repeats 5 and 6 of β-catenin reduce binding to APC, increasing signaling and transcription of target genes
Gastroenterology, Epub Dec. 2019. | PubMed Link | Link to the Journal - Xu M, Wang J, Xu Z, Li R, Wang P, Sang R, Evert K, Wang H, Song X, Zhang S, Che L, Calvisi DF, Liu Q and Chen X
SNAI1 promotes cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma mode
Cancer Research, Epub Aug. 2019. | PubMed Link | Link to Journal - Liu X, Hu J, Song X, Utpatel K, Zhang Y, Wang P, Lu X, Zhang J, Che Li, Evert M, Calvisi DF and Chen X
Combined treatment with MEK and mTOR inhibitors is effective in vitro and in vivo models of hepatocellular carcinoma
Cancers, Vol. 11(7), Jul. 2019, E930. | PubMed Link | Link to the Journal - Xu Z, Xu M, Liu P, Zhang S, Shang R, Qiao Y, Che L, Ribback S, Evert K, Pascale RM, Dombrowski F, Evert M, Liu Q, Calvisi DF and Chen X
The mTORC2-Akt1 cascade is crucial of c-Myc to promote hepatocarcinogenesis in mice and men
Hepatology, Epub. | PubMed Link | Link to the Journal - Wang J, Wang H, Peter W, Ding N, Ribback S, Utpatel K, Cigliano A, Dombrowski F, Xu M, Chen X, Song X, Evert M, Cossu A, Gordan J, Zeng Y, Chen X# and Calvisi DF# (#Co-corresponding authors)
Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis
Journal of Hepatology, Epub | PubMed Link | Link to the Journal - Cao H, Xu Z, Wang J, Cigliano A, Pilo MG, Ribback S, Zhang S, Qiao Y, Che L, Pascale RM, Calvisi DF and Chen X
Functional Role of SGK3 in PI3K/Pten driven liver tumor development
BMC Cancer, Vol. 19(1), Apr. 2019: 343. | PubMed Link | Link to the Journal - Che L, Chi W, Qiao Y, Liu Y, Li L, Jai J, Pilo MG, Wang J, Cigliano A, Ma Z, Kuang W, Tang Z, Zhang Z, Shui G, Ribback S, Dombrowski F, Cossu C, Pes GM, Osborne TF, Calvisi DF#, Chen X# and Chen L# (#Co-corresponding authors)
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans
Gut, Epub Apr. 2019. | PubMed Link | Link to the Journal - Chen X, Monga SP and Calvisi DF
Reply (to LET HEP-19-0392)
Hepatology, Epub. Apr. 2019
- Wang P, Song X, Utpatel K, Sang R, Yang YM, Xu M, Zhang J, Che L, Gordan J, Cigliano A, Seki E, Evert M, Calvisi DF, Hu X and Chen X
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
Cell Death and Disease, 2019 Feb 11;10(2):120. | PubMed Link | Link to the Journal - Zhang J, Liu P, Tao J, Wna P, Che L, Sumazin P, Ribback S, Kiss An, Schaff Z, Cigliano A, Dombrowski F, Cossu C, Pascale RM, Calvisi DF, Monga SP and Chen X
TEA domain transcription factor 4 (TEAD4) is the major mediator of Yap oncogenic activity in mouse and human hepatoblastoma
American Journal of Pathology, 2019 Feb 19. pii: S0002-9440(18)30776-4. | PubMed Link | Link to the Journal - Qiao Y, Wang J, Karagoz E, Song X, Ever K, Xu M, Che L, Evert M, Calvisi DF, Tao J, Wang B, Monga SP and Chen X
Deletion of Axin1 induced hepatocarcinogenesis requires intact β-catenin but not Notch cascade in mice
Hepatology, Epub 2019 Feb 8.| PubMed Link | Link to the Journal
2018
- Ribback S, Che L, Pilo MG, Cigliano A, Latte G, Pes GM, Porcu A, Pascale RM, Li L, Qiao Y, Dombrowski F, Chen X# and Calvisi DF# (#Co-corresponding authors)
Oncogene-dependent addiction to Carbohydrate-Responsive Element Binding Protein in hepatocellular carcinoma
Cell Cycle, Jul. 2018, pp1-18| PubMed Link | Link to the Journal - Song X, Liu X, Wang H, Wang J, Qiao Y, Cigliano A, Utpatel K, Ribback S, Pilo M, Serra M, Gordan J, Che L, Zhang S, Cossu A, Porcu A, Pascale RM, Donbrowski F, Hu H, Calvisi DF, Evert M and Chen X
Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma
Clinical Cancer Research, 2019 Jan 1;25(1):403-413| PubMed Link | Link to the Journal : Commentary by Malumbres M: “CDK4/6 inhibitors: What is the best cocktail?” | PubMed Link | Link to the Journal - Liu X, Song X, Zhang J, Xu Z, Che L, Cigliano A, Pascale RM, Calvisi DF, Liu Y and Chen X.
Focal adhesion kinase (FAK) activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma
Cancer Medicine, 2018 Dec;7(12):6170-6181. | PubMed Link | Link to the Journal - Yan Z, Grenert JP, Joseph NM, Ren C, Chen X, Shafizadeh N and Kakar S.
Hepatic Angiomyolipoma: Mutation analysis of immunohistochemical pitfalls in diagnosis
Histopathology, Vol. 73(1), Jul. 2018, pp101-108| PubMed Link | Link to the Journal - Wang J, Dong M, Xu Z, Zhang S, Song X, Che L, Gordan J, Hu K, Liu Y, Calvisi DF and Chen X.
Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
Oncogene, Vol. 37(24), Jun. 2018, pp3229-3242| PubMed Link | Link to the Journal - Xu Z, Hu J, Cao H, Che L, Pilo M, Cigliano A, Xu M, Ribback S, Dombrowski F, Calvisi DF and Chen X.
Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
Experimental & Molecular Medicine, Vol. 50(1), Jan. 2018, e417| PubMed Link | Link to the Journal - Dong M, Liu X, Evert K, Utpatel K, Peters M, Zhang S, Xu Z, Che L, Cigliano A, Ribback S, Dombrowski F, Cossu A, Gordan J, Clavisi DF, Evert M, Liu Y and Chen X
Efficacy of MEK inhibition in a K-Ras driven cholangiocarcinoma preclinical model.
Cell Death and Disease, Vol. 9(2), Jan. 2018, 31| PubMed Link | Link to the Journal - Zhang S, Wang J, Fan L, Fan B, Tao J, Li X, Chen L, Cigliano A, Ribback S, Dombrowski F, Chen B, Wei L, Calvisi DF and Chen X.
Hippo cascade controls differentiation status in AKT/Ras-driven liver cancer development in mice.
American Journal of Pathology, 2018 Apr;188(4):995-1006.| PubMed Link | Link to the Journal
2017
- Cigliano A, Pilo MG, Li L, Latte G, Szydlowska M, Simile MM, Paliogiannis P, Pes GM, Palmieri G, Sini MC, Cossu A, Rascale RM, Ribback S, Dombrowski F, Chen X# and Calvisi DF# (#Co-corresponding authors):
Deregulated c-Myc requires a functional HSF1 for hepatocarcinogenesis
Oncotarget, Vol. 8(53), Oct. 2017, pp90638-90650| PubMed Link | Link to the Journal - Caviglia JM, Yan J, Jan MK, Gwak GY, Affo S, Yu L, Olinga P, Friedman RA, Chen X and Schwabe RF
MicroRNA-21 and dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis.
Hepatology, Jun;67(6):2414-2429 | PubMed Link | Link to the Journal - Liu P, Calvisi DF, Kiss A, Cigliano A, Schaff Z, Che L, Ribback S, Dombrowski F, Zhao D and Chen X.
Central role of mTORC1 downstream of Yap/TAZ in hepatoblastoma development.
Oncotarget, Vol. 8(43), Sep. 2017, pp73433-73447| PubMed Link - Jia J, Qiao Y, Pilo MG, Cigliano A, Liu X, Shao Z, Calvisi DF and Chen X .
Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade.
PLoS One, Vol. 12(9), Sep. 2017, e0184068| PubMed Link | Link to the Journal - Mendez-Lucas A, Li X, Hu J, Che L, Song X, Jia J, Xie C, Driscoll PC, Tschaharganeh DF, Calvisi DF, Yuneva M and Chen X .
Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1/PKM2 ratios and pyruvate kinase activities.
Cancer Research, 2017 Aug 15;77(16):4355-4364. | PubMed Link | Link to the Journal - Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, Hu J, Chen B, Dong M, Pilo MG, Cialiano A, Evert K, Ribback S, Dombrowski F, Pascale RM, Cossu A, Vidili G, Porcu A, Simile MM, Pes GM, Giannelli G, Gordan J, Wei L, Evert M, Cong W, Calvisi DF and Chen X.
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Journal of Hepatology, 2017 Dec;67(6):1194-1203 | PubMed Link | Link to the Journal - Wu H, Tao J, Li X, Zhang T, Fan S, Steer CJ, Chen X#, and Song G.# (#Co-corresponding authors).
microRNA-206 prevents the pathogenesis of hepatocellular carcinoma via modulating cMet and Cdk6.
Hepatology, 2017 Dec;66(6):1952-1967 | PubMed Link | Link to the Journal - Cigliano A, Wang C, Pilo MG, Szydlowska M, Brozzetti S, Latte G, Pes GM, Pascale RM, Seddaiu MA, Vidili G, Ribback S, Donbrowski F, Evert M, Chen X#, and Calvisi DF# (#Co-corresponding authors).
Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice
Oncotarget, 2017 Apr 7;8(33):54149-54159. | PubMed Link - Oliveira DV, Zhang S, Chen X, Calvisi DF and Andersen JB.
Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets
Expert Rev Gastroenterol Hepatol,Vol. 11(4), Apr. 2017, pp349-356 | PubMed Link | Link to the Journal - Cigliano A, Wang J, Chen X,and Calvisi DF.
Role of Notch signaling in cholangiocarcinoma.
Expert Opin Ther Targets, Vol. 21(5), May. 2017, pp471-483 | PubMed Link | Link to the Journal - Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo M, Cialiano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Ta J, Calvisi DF, Chen L and Chen X.
A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis.
Hepatology Epub Mar. 2017 | PubMed Link | Link to the Journal - Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X# ,and Calvisi F# (#Co-corresponding authors).
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
Cell Cycle, Epub Jan. 2017 | PubMed Link | Link to the Journal
2016
- Wu H, Zhang T, Pan F, Steer CJ, Li Z, Chen X, and Song G.
MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis
Journal of Hepatology, Epub Dec. 2016 | PubMed Link | Link to the Journal - Tao J, Zhang R, Singh S, Poddar M, Xu E, Oertel M, Chen X, Ganesh S, Abrams M and Monga SP.
Targeting β-catenin in hepatocellular cancers induced by co-expression of mutant β-catenin and K-Ras in mice
Hepatology Epub Dec. 2016 | PubMed Link | Link to the Journal - Chen X,and Calvisi DF
The dark side of the moon: AKT as a tumor suppressor in the liver
Hepatology, Vol. 64(4), Oct. 2016, pp1358-1361 | PubMed Link | Link to the Journal - Che L, Fan B, Pilo MG, Xu Z, Liu Y, Cigliano A, Cossu A, Palmieri G, Pascale RM, Porcu A, Vidili G, Serra M, Dombrowski F, Ribback S, Calvisi DF and Chen X.
Jagged 1 is a major Notch ligand alone cholangiocarcinoma development in mice and humans
Oncogenesis, Vol. 5(12), Dec. 2016, e274 | PubMed Link - Tao J, Xu E, Zhao Y, Singh S, Li X, Couchy G, Chen X, Zucman-Rossi J, Chikina M, Monga SP
Modeling a human HCC subset in mice through co-expression of MET and point-mutant β-catenin
Hepatology, Epub Apr. 2016 | PubMed Link | Link to the Journal - Cao D, Song X, Che L, Li X, Pilo MG, Vidili G, Porcu A, Solinas A, Cigliano A, Ribback S, Dombrowski F, Chen X, Li L and Calvisi DF
Both de novo synthetized and exogenous fatty acid support the growth of hepatocellular carcinoma cells
Liver International, Epub Jun. 2016 | PubMed Link | Link to the Journal - Hale G, Liu X, Hu J, Xu Z, Che L, Solomon D, Tsokos C, Shafizadeh N, Chen X, Gill R and Kakar S
Correlation of β-catenin exon 3 mutations with Glutamine Synthetase patterns in hepatocellular carcinoma and hepatocellular adenoma
Modern Pathology, Epub Jul. 2016 | PubMed Link -
Samarin J, Laketa V, Malz M, Roessler S, Stein I, Horwitz E, Singer S, Dimou E, Cigliano A, Falk CS, Chen X,Dooley S, Pikarsky E, Calvisi DF, Schultz C, Schirmacher P and Breuhahn K.
PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells
Hepatology, Vol. 63(3), Mar. 2016, pp813-826 | PubMed Link | Link to the Journal -
Li L, Che L, Tharp KM, Park HM, Pilo MG, Can D, Cigliano A, Latte G, Xu Z, Ribback S, Dombrowski F, Evert M, Gores GJ, Stahl A, Calvisi DF and Chen X.
Differential requirement of de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans
Hepatology, Epub Feb. 2016 | PubMed Link | Link to the Journal -
Hu J, Che L, Li L, Pilo GM, Cigliano A, Ribback S, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X# and Calvisi DF# (#Co-corresponding authors).
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via mTORC1/FASN pathway in mice
Scientific Reports, Epub Feb. 2016 | PubMed Link |
Link to the Journal -
Ding N, Che L, Li X, Liu Y, Jiang L, Fan B, Tao J, Chen X and Ji JF.
Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice
World Journal of Gastroenterology, Vol. 22(6), Feb. 2016, pp2071-2080 | PubMed Link | Link to the Journal
